|Bid||64.50 x 400|
|Ask||64.59 x 2000|
|Day's Range||64.31 - 64.75|
|52 Week Range||63.88 - 88.85|
|PE Ratio (TTM)||6.82|
|Dividend & Yield||2.08 (3.22%)|
|1y Target Est||N/A|
In 2016, Gilead Sciences’ (GILD) Truvada generated revenues of around $3.1 billion, reflecting ~3% year-over-year growth.
Gilead Sciences’ (GILD) HCV franchise was the company's highest revenue-generating division back in 2015.
Conservatively, this cancer drug is expected to generate between $8 billion and $8.3 billion in full-year sales.